Brought to you by 
Zeneca increases its stake in Sugen and announces alliance
13 Jul 1999
Executive Summary
Zeneca Group and Sugen (signal transduction) announced a broad alliance to co-develop anti-cancer drugs. Zeneca will buy 789,141 Sugen common shares for $12.5 mm ($15.84 per share, currently trading at $7.00), increasing its stake from 12.5 to 20%.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zeneca increases its stake in Sugen and announces alliance
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice